BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kiso M, Lopes TJS, Yamayoshi S, Ito M, Yamashita M, Nakajima N, Hasegawa H, Neumann G, Kawaoka Y. Combination Therapy With Neuraminidase and Polymerase Inhibitors in Nude Mice Infected With Influenza Virus. J Infect Dis 2018;217:887-96. [PMID: 29186472 DOI: 10.1093/infdis/jix606] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 8.3] [Reference Citation Analysis]
Number Citing Articles
1 Tilmanis D, Koszalka P, Barr IG, Rossignol J, Mifsud E, Hurt AC. Host-targeted nitazoxanide has a high barrier to resistance but does not reduce the emergence or proliferation of oseltamivir-resistant influenza viruses in vitro or in vivo when used in combination with oseltamivir. Antiviral Research 2020;180:104851. [DOI: 10.1016/j.antiviral.2020.104851] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
2 Ison MG, Hayden FG, Hay AJ, Gubareva LV, Govorkova EA, Takashita E, McKimm-Breschkin JL. Influenza polymerase inhibitor resistance: Assessment of the current state of the art - A report of the isirv Antiviral group. Antiviral Res 2021;194:105158. [PMID: 34363859 DOI: 10.1016/j.antiviral.2021.105158] [Reference Citation Analysis]
3 Mhamdi Z, Fausther-Bovendo H, Uyar O, Carbonneau J, Venable MC, Abed Y, Kobinger G, Boivin G, Baz M. Effects of Different Drug Combinations in Immunodeficient Mice Infected with an Influenza A/H3N2 Virus. Microorganisms 2020;8:E1968. [PMID: 33322333 DOI: 10.3390/microorganisms8121968] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Seki M, Sakai-Tagawa Y, Yasuhara A, Watanabe Y. Adult influenza A (H3N2) with reduced susceptibility to baloxavir or peramivir cured after switching anti-influenza agents. IDCases 2019;18:e00650. [PMID: 31692637 DOI: 10.1016/j.idcr.2019.e00650] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
5 Takashita E. Influenza Polymerase Inhibitors: Mechanisms of Action and Resistance. Cold Spring Harb Perspect Med 2021;11:a038687. [PMID: 32122918 DOI: 10.1101/cshperspect.a038687] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 15.0] [Reference Citation Analysis]
6 Fukao K, Ando Y, Noshi T, Kitano M, Noda T, Kawai M, Yoshida R, Sato A, Shishido T, Naito A. Baloxavir marboxil, a novel cap-dependent endonuclease inhibitor potently suppresses influenza virus replication and represents therapeutic effects in both immunocompetent and immunocompromised mouse models. PLoS One 2019;14:e0217307. [PMID: 31107922 DOI: 10.1371/journal.pone.0217307] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
7 Lee N, Ison MG. Inhibiting Viral Polymerase and Neuraminidase in Treating Influenza. The Journal of Infectious Diseases 2019;219:1013-5. [DOI: 10.1093/infdis/jiy548] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
8 Lee N, Hurt AC. Neuraminidase inhibitor resistance in influenza: a clinical perspective. Curr Opin Infect Dis 2018;31:520-6. [PMID: 30299356 DOI: 10.1097/QCO.0000000000000498] [Cited by in Crossref: 41] [Cited by in F6Publishing: 18] [Article Influence: 13.7] [Reference Citation Analysis]
9 Tu V, Abed Y, Fage C, Baz M, Boivin G. Impact of R152K and R368K neuraminidase catalytic substitutions on in vitro properties and virulence of recombinant A(H1N1)pdm09 viruses. Antiviral Res 2018;154:110-5. [PMID: 29674164 DOI: 10.1016/j.antiviral.2018.04.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
10 Pascua PNQ, Marathe BM, Vogel P, Webby RJ, Govorkova EA. Optimizing T-705 (favipiravir) treatment of severe influenza B virus infection in the immunocompromised mouse model. J Antimicrob Chemother 2019;74:1333-41. [PMID: 30715325 DOI: 10.1093/jac/dky560] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
11 Hayden FG, Shindo N. Influenza virus polymerase inhibitors in clinical development. Curr Opin Infect Dis 2019;32:176-86. [PMID: 30724789 DOI: 10.1097/QCO.0000000000000532] [Cited by in Crossref: 91] [Cited by in F6Publishing: 48] [Article Influence: 45.5] [Reference Citation Analysis]
12 Mahal A, Duan M, Zinad DS, Mohapatra RK, Obaidullah AJ, Wei X, Pradhan MK, Das D, Kandi V, Zinad HS, Zhu Q. Recent progress in chemical approaches for the development of novel neuraminidase inhibitors. RSC Adv 2021;11:1804-40. [DOI: 10.1039/d0ra07283d] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
13 Baz M, Carbonneau J, Rhéaume C, Cavanagh MH, Boivin G. Combination Therapy with Oseltamivir and Favipiravir Delays Mortality but Does Not Prevent Oseltamivir Resistance in Immunodeficient Mice Infected with Pandemic A(H1N1) Influenza Virus. Viruses 2018;10:E610. [PMID: 30400276 DOI: 10.3390/v10110610] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
14 Lu W, Pieters RJ. Carbohydrate–protein interactions and multivalency: implications for the inhibition of influenza A virus infections. Expert Opinion on Drug Discovery 2019;14:387-95. [DOI: 10.1080/17460441.2019.1573813] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
15 Mifsud EJ, Hayden FG, Hurt AC. Antivirals targeting the polymerase complex of influenza viruses. Antiviral Res 2019;169:104545. [PMID: 31247246 DOI: 10.1016/j.antiviral.2019.104545] [Cited by in Crossref: 61] [Cited by in F6Publishing: 56] [Article Influence: 20.3] [Reference Citation Analysis]
16 Yamazaki T, Chiba J, Akashi-Takamura S. Neutralizing Anti-Hemagglutinin Monoclonal Antibodies Induced by Gene-Based Transfer Have Prophylactic and Therapeutic Effects on Influenza Virus Infection. Vaccines (Basel) 2018;6:E35. [PMID: 29949942 DOI: 10.3390/vaccines6030035] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
17 Tomozawa T, Hoshino K, Yamashita M, Kubo S. Efficacy of laninamivir octanoate in mice with advanced inflammation stage caused by infection of highly lethal influenza virus. J Infect Chemother 2019;25:584-8. [PMID: 30935767 DOI: 10.1016/j.jiac.2019.02.023] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
18 Kiso M, Yamayoshi S, Murakami J, Kawaoka Y. Baloxavir Marboxil Treatment of Nude Mice Infected With Influenza A Virus. J Infect Dis 2020;221:1699-702. [PMID: 31837268 DOI: 10.1093/infdis/jiz665] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
19 Xing X, Hu S, Chen M, Zhan F, Liu H, Chen Z, Zhang H, Zeng G, Xu Q, Zhang H, Liu M, Liu H, Gao L, Zhang L. Severe acute respiratory infection risk following glucocorticosteroid treatment in uncomplicated influenza-like illness resulting from pH1N1 influenza infection: a case control study. BMC Infect Dis 2019;19:1080. [PMID: 31878888 DOI: 10.1186/s12879-019-4669-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
20 Du Pont V, Plemper RK, Schnell MJ. Status of antiviral therapeutics against rabies virus and related emerging lyssaviruses. Curr Opin Virol 2019;35:1-13. [PMID: 30753961 DOI: 10.1016/j.coviro.2018.12.009] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
21 Kiso M, Yamayoshi S, Kawaoka Y. Triple combination therapy of favipiravir plus two monoclonal antibodies eradicates influenza virus from nude mice. Commun Biol 2020;3:219. [PMID: 32382088 DOI: 10.1038/s42003-020-0952-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]